Precision BioSciences Confirms Nasdaq Listing & Common Stock Details

TL;DR

**DTIL confirms Nasdaq listing, business as usual.**

AI Summary

Precision BioSciences, Inc. filed an 8-K on January 19, 2024, to report that it is a registrant with its Common Stock, par value $0.000005 per share, traded on The Nasdaq Capital Market under the symbol DTIL. This filing confirms the company's compliance with SEC reporting requirements and its continued listing on a major exchange. For investors, this matters because it reaffirms the company's public status and the liquidity of its shares, which is fundamental for trading and valuation.

Why It Matters

This filing confirms Precision BioSciences' ongoing compliance with SEC regulations and its continued listing on The Nasdaq Capital Market, ensuring its shares remain publicly tradable.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing confirming basic company information and exchange listing, posing minimal risk.

Analyst Insight

This filing is purely administrative and does not provide new information that would warrant an immediate investment action. Investors should continue to monitor operational and financial performance filings.

Key Numbers

• $0.000005 — Par Value per Share (The stated par value of Precision BioSciences' Common Stock.)

Key Players & Entities

• Precision BioSciences, Inc. (company) — the registrant filing the 8-K
• The Nasdaq Capital Market (company) — the exchange where DTIL's common stock is registered
• $0.000005 (dollar_amount) — par value per share of common stock
• DTIL (company) — trading symbol for Precision BioSciences, Inc.
• January 18, 2024 (date) — date of earliest event reported

FAQ

Key Financial Figures

• $0.000005 — ch registered Common Stock, par value $0.000005 per share DTIL The Nasdaq Capital M

Filing Documents

• dtil-20240118.htm (8-K) — 56KB
• 0000950170-24-005581.txt ( ) — 174KB
• dtil-20240118.xsd (EX-101.SCH) — 27KB
• dtil-20240118_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On January 18, 2024, the Company held a special meeting of stockholders (the “Special Meeting”). A total of 83,328,647 shares of the Company’s common stock, par value $0.000005 (the “Common Stock”), were present in person or represented by proxy at the Special Meeting, representing approximately 68.34% of the Common Stock outstanding as of the November 27, 2023 record date. Following are the voting results for the proposals considered and voted upon at the Special Meeting, each of which were described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on December 4, 2023, as supplemented. Proposal 1 – The approval of amendments to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the Company’s Common Stock at a ratio ranging from any whole number between 1-for-10 and 1-for-30, as determined by the Company’s Board of Directors (the “Board”) in its discretion, subject to the Board’s authority to abandon such amendments. Votes FOR Votes AGAINST Votes ABSTAINED BROKER NON-VOTES 71,771,593 11,275,251 281,803 0 Proposal 2 – The approval of an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve Proposal 1. Votes FOR Votes AGAINST Votes ABSTAINED BROKER NON-VOTES 75,291,080 7,698,338 339,229 0 Based on the foregoing votes, the affirmative vote of the holders of a majority of the voting power of the votes cast at the Special Meeting has been voted in favor for both proposals. Although Proposal 2 was approved, adjournment of the Special Meeting was not necessary or appropriate because the Company’s stockholders approved Proposal 1.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRECISION BIOSCIENCES, INC. Date: January 19, 2024 By: /s/ Dario Scimeca Dario Scimeca General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR